Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility
- PMID: 11320171
- DOI: 10.1212/wnl.56.8.1015
Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility
Abstract
Background: Thrombolytic therapy for acute stroke (<3 hours) will not have a major impact on death and dependency unless it is accessible to more patients.
Objective: To determine why patients with ischemic stroke did not receive IV TPA and assess the availability of this therapy to patients with ischemic stroke.
Methods: Consecutive patients with acute ischemic stroke were prospectively identified at a university teaching hospital between October 1996 and December 1999. Additional patients with ischemic stroke were identified that were admitted to one of three other hospitals in the Calgary region during the study period. The Oxford Community Stroke Programme Classification was used to record type and side of stroke.
Results: Of 2165 stroke patients presenting to the university hospital, 1168 (53.9%) were diagnosed with ischemic stroke, 31.8% with intracranial hemorrhage (intracerebral, subarachnoid, or subdural), and 13.9% with TIA. Delay in presentation to emergency department beyond 3 hours excluded 73.1% (854/1168). Major reasons for delay included uncertain time of onset (24.2%), patients waited to see if symptoms would improve (29%), delay caused by transfer from an outlying hospital (8.9%), and inaccessibility of treating hospital (5.7%). Twenty-seven percent of patients with ischemic stroke (314/1168) were admitted within 3 hours of sympton onset and of these 84 (26.7%) patients received IV TPA. The major reasons for exclusion in this group of patients (<3 hours) were mild stroke (13.1%), clinical improvement (18.2%), perceived protocol exclusions (13.6%), emergency department referral delay (8.9%), and significant comorbidity (8.3%). Of those patients who were considered too mild or were documented to have had significant improvement, 32% either remained dependent at hospital discharge or died during hospital admission. Throughout the region there was a total of 1806 ischemic stroke patients (admitted to all four Calgary hospitals). During this study period, 4.7% received IV TPA.
Conclusions: The majority of patients are unable to receive TPA for acute ischemic stroke because they do no not reach the hospital soon enough. Of those patients presenting within 3 hours, 27% received the therapy but a further 31% were excluded because their symptoms were either considered too mild or were rapidly improving. Subsequently, a third of these patients were left either dependent or dead, bringing into question the initial decision not to treat.
Comment in
-
Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility.Neurology. 2001 Nov 13;57(9):1739-40. doi: 10.1212/wnl.57.9.1739. Neurology. 2001. PMID: 11706134 No abstract available.
Similar articles
-
Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.J Stroke Cerebrovasc Dis. 2013 Apr;22(3):190-6. doi: 10.1016/j.jstrokecerebrovasdis.2011.07.016. Epub 2011 Oct 2. J Stroke Cerebrovasc Dis. 2013. PMID: 21968092
-
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.Arch Neurol. 2004 Mar;61(3):346-50. doi: 10.1001/archneur.61.3.346. Arch Neurol. 2004. PMID: 15023810
-
Barriers to the use of intravenous tissue plasminogen activator for in-hospital strokes.J Stroke Cerebrovasc Dis. 2012 Nov;21(8):808-11. doi: 10.1016/j.jstrokecerebrovasdis.2011.04.012. Epub 2011 Jun 2. J Stroke Cerebrovasc Dis. 2012. PMID: 21640608
-
Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.Stroke. 2006 Jul;37(7):1917-22. doi: 10.1161/01.STR.0000226651.04862.da. Epub 2006 May 25. Stroke. 2006. PMID: 16728683 Review.
-
Role of tissue plasminogen activator in acute ischemic stroke.Ann Pharmacother. 2011 Mar;45(3):364-71. doi: 10.1345/aph.1P525. Epub 2011 Mar 8. Ann Pharmacother. 2011. PMID: 21386027 Review.
Cited by
-
High-intensity focused ultrasound (HIFU) for dissolution of clots in a rabbit model of embolic stroke.PLoS One. 2012;7(8):e42311. doi: 10.1371/journal.pone.0042311. Epub 2012 Aug 1. PLoS One. 2012. PMID: 22870315 Free PMC article.
-
Prediction factors of recurrent ischemic events in one year after minor stroke.PLoS One. 2015 Mar 16;10(3):e0120105. doi: 10.1371/journal.pone.0120105. eCollection 2015. PLoS One. 2015. PMID: 25774939 Free PMC article.
-
Reasons and evolution of non-thrombolysis in acute ischaemic stroke.Emerg Med J. 2017 Apr;34(4):219-226. doi: 10.1136/emermed-2015-205140. Epub 2016 Oct 25. Emerg Med J. 2017. PMID: 27797870 Free PMC article.
-
Reasons for Exclusion From Intravenous Thrombolysis in Acute Ischemic Stroke: Experience From a Moroccan Stroke Unit.Cureus. 2023 Jan 2;15(1):e33248. doi: 10.7759/cureus.33248. eCollection 2023 Jan. Cureus. 2023. PMID: 36741618 Free PMC article.
-
Glia-immune interactions post-ischemic stroke and potential therapies.Exp Biol Med (Maywood). 2018 Dec;243(17-18):1302-1312. doi: 10.1177/1535370218818172. Epub 2018 Dec 11. Exp Biol Med (Maywood). 2018. PMID: 30537868 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical